Ian A. Cook
Hoofd Techniek/Wetenschap/O&O bij NeuroSigma, Inc.
Profiel
Ian A.
Cook is currently the Director of the Transcranial Magnetic Stimulation Service at the Semel Institute for Neuroscience & Human Behavior, Chief Medical Officer & Senior Vice President at NeuroSigma, Inc., Professor at the David Geffen School of Medicine, and Professor at the Henry Samueli School of Engineering & Applied Science.
He received his undergraduate degree from Princeton University and his doctorate from Yale School of Medicine.
Actieve functies van Ian A. Cook
Bedrijven | Functie | Begin |
---|---|---|
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | Hoofd Techniek/Wetenschap/O&O | 01-01-2014 |
Henry Samueli School of Engineering & Applied Science | Corporate Officer/Principal | 01-07-2013 |
David Geffen School of Medicine | Corporate Officer/Principal | 01-07-2010 |
Semel Institute For Neuroscience & Human Behavior | Corporate Officer/Principal | 01-01-2007 |
Opleiding van Ian A. Cook
Princeton University | Undergraduate Degree |
Yale School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | Health Technology |